2 Vaccines: So Far, So Good
It’s still early days for 2 coronavirus vaccine candidates, but trial results published yesterday in The Lancet earned promising (though qualified) results.
The first vaccine, developed by Oxford University and AstraZeneca and sporting the catchy name of ChAdOx1 nCoV-19, safely generated strong immune responses in a trial involving 1,000+ patients, according to a Lancet article reported on by The Washington Post.
Larger phase 3 trials of the vaccine are already underway in the UK, Brazil, and South Africa with results expected sometime this fall, STAT reports.
Another Lancet article reports that a CanSino Biologics vaccine successfully “induced neutralizing antibody responses” but didn’t work as well for people 55+, STAT reports.
And Bloomberg Opinion columnist Max Nisen warns against jumping on every piece of positive news about vaccines. The real test of their effectiveness requires waiting for “big real-world confirmatory trials,” Nisen writes in The Washington Post.